Green Cross received approval for the Phase II clinical trial of 'Hepabig-gene' from Ministry of Food and Drug Safety

Published: 2014-08-29 09:24:41

Updated: 2014-08-29 09:48:19

On August 27, Green Cross announced that they received approval for the Phase II test plan of 'Hepabig-gene' which is gene recombinant hepatitis B immune globulin from Ministry of Food and Drug Safety.

'Hepabig-gene' is gene recombination method hepatitis B antibody treatment (Bio new drug). 'Hepabig-gene' has a high purity and excellent capability to neutralize hepatitis B virus compared to ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.